US equities |
MU $928.20 ▼-2.62% NVDA $222.39 ▼-2.68% AAPL $345.31 ▲+1.18% META $738.15 ▼-3.19% SPCX $153.55 ▼-1.91% TSLA $365.62 ▼-2.56% SNDK $1,425.63 ▼-3.83% AMD $577.33 ▼-4.66%
FinancialContent

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

3.755 -0.085 (-2.21%)
Delayed Quote Updated: 11:57 AM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
News headline image
Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley Conference ↗
Recursion Pharmaceuticals (NASDAQ:RXRX) outlined its strategy, clinical pipeline and partnership progress at Morgan Stanley’s Global Healthcare Conference, with CEO and President Najat Khan emphasizing... 
Via MarketBeat
Topics Artificial Intelligence
News headline image
2 Beaten-Down Stocks to Avoid Right Now ↗
Don't catch a falling knife. 
Via The Motley Fool
News headline image
The Market Just Told You Which Layer Of AI Biology It Is Paying For
Issued on behalf of MindWalk Holdings Corp. 
From Market Updates
Via GlobeNewswire
Recursion Pharmaceuticals (RXRX) Q1 2026 Results: Revenue Miss Overshadows Narrower Net Loss ↗
Via Chartmill
News headline image
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates ↗
Recursion Pharmaceuticals (NASDAQ:RXRX) is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and... 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Recursion (RXRX) Q2 2026 Earnings Call Transcript ↗
AI-native drug discovery advances neuroscience target with Roche while cutting cash guidance. 
Via The Motley Fool
Topics Artificial Intelligence Earnings
News headline image
Recursion Pharmaceuticals Q2 Earnings Call Highlights ↗
Recursion Pharmaceuticals (NASDAQ:RXRX) outlined progress across its clinical pipeline, drug-discovery partnerships and AI-enabled research platform, while lowering its 2026 cash operating expense... 
Via MarketBeat
Topics Artificial Intelligence Earnings
News headline image
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
3 Stocks With the Most Upside by the End of 2026 ↗
Analysts remain optimistic that the market will view upcoming catalysts in a bullish light. 
Via The Motley Fool
Topics Workforce
News headline image
Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th
Company to host public Earnings call on August 5th at 8:00 am ET / 6:00 am MT / 1:00 pm BST 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Cathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy? ↗
Cathie Wood's Ark Genomic Revolution ETF owns $50 million worth of Recursion Pharmaceuticals stock. 
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
2 Beaten-Down Stocks That Still Aren't Worth Buying ↗
Your hard-earned money would be better spent elsewhere. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
Two stocks that have fallen out of favor and one hot stock that was one of Thursday's biggest losers were on the Ark Invest founder's shopping list. 
Via The Motley Fool
Topics ETFs
News headline image
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026? ↗
Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, and industry partnerships. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026? ↗
Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles. 
Via The Motley Fool
News headline image
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up? 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Market ↗
Yes, many of the companies you've invested in also have their own stock portfolios. This is bullishness worth noting. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying ↗
These aren't for the faint of heart. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026? ↗
Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now? ↗
The stock looks cheap, but appearances can be deceiving. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
A Deep Dive Into NVIDIA’s Latest Portfolio Moves ↗
NVIDIA's latest 13F filing does not tell the story it seems to at first glance. The apparent divergence in its CoreWeave and Nebius holdings is a prime example. 
Via MarketBeat
Topics Artificial Intelligence Economy Regulatory Compliance
TechMediaBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Advances AI Voice-Based Intoxication Detection as Real-Time Diagnostics Market Expands
Via Investor Brand Network
Topics Artificial Intelligence
The Future of Intoxication Detection May Be in Your Voice
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
The Future of Intoxication Detection May Be in Your Voice
From BioMedWire
Via GlobeNewswire
News headline image
3 Stocks Poised to Disrupt the Healthcare Market by 2030 ↗
The old healthcare model is breaking down. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Recursion (RXRX) Q1 2026 Earnings Transcript ↗
Recursion (RXRX) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >